Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

This early-phase study is testing the safety of IPH4502, a new experimental drug, in people with advanced solid tumors that express a protein called Nectin-4. This includes cancers like bladder, lung, breast, and cervical cancer. The goal is to find a safe dose and understand how the body processes the drug. **You may be eligible if...** - You have advanced or metastatic solid cancer known to express Nectin-4 - You have received prior treatments but have no more standard options available - You have measurable disease on imaging - Your organ function is adequate **You may NOT be eligible if...** - You have known or suspected brain metastases - You have active or serious infections - You have interstitial lung disease - You are on systemic steroids or immune-suppressing drugs - You have had a recent blood clot requiring anticoagulation Talk to your doctor to see if this trial is right for you.